Dynavax Technologies (DVAX) Expected to Post Quarterly Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) is expected to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $15.50 on Tuesday. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -41.89 and a beta of 0.97. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $15.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The stock has a fifty day moving average price of $14.49 and a 200-day moving average price of $11.85.

Analysts Set New Price Targets

DVAX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Wall Street Zen raised shares of Dynavax Technologies to a “strong-buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $24.33.

Insider Buying and Selling at Dynavax Technologies

In related news, COO David F. Novack sold 114,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the transaction, the chief operating officer directly owned 63,344 shares in the company, valued at $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.98% of the company’s stock.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Parkman Healthcare Partners LLC grew its stake in shares of Dynavax Technologies by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock worth $2,694,000 after acquiring an additional 1,175 shares during the period. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Dynavax Technologies by 1.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 1,610 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dynavax Technologies by 1.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 1,625 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Dynavax Technologies by 17.9% in the second quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,752 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.